Press Release
World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board
In his work at
“I have a deep passion and commitment for transforming science into life-saving and life-improving inventions and I am delighted to be a member of Daré’s
Currently, Dr. Langer is the most cited engineer in history. He has authored over 1,400 articles, and holds over 1,350 issued and pending patents worldwide. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.
“We are truly honored to have Dr. Langer join our distinguished board of scientific advisors,” said
Dr. Langer has received over 220 major awards and is one of seven individuals to have received both the United States National Medal of Science, in 2006, and the United States National Medal of Technology and Innovation, in 2011. Dr. Langer also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s largest technology prize. In 2012 he received the Priestley Medal, the highest award of the
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-class candidates in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of the company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Burns McClellan
agray@burnsmc.com
212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:
amanda@canalecomm.com
781-405-8775
Source: Daré Bioscience
Source: Dare Bioscience, Inc.